Cingulate (CINGW) Other Working Capital Changes (2021 - 2025)
Cingulate's (CINGW) quarterly Other Working Capital Changes came in at -$248697.0 in Q4 2025, up 75.55% on a YoY basis from -$141668.9 in Q4 2024, and down 3287.78% quarter-over-quarter from -$7341.0 in Q3 2025.
Analysis
Cingulate (CINGW) Other Working Capital Changes (2021 - 2025) Analysis & Trends
Cingulate (CINGW) has reported Other Working Capital Changes for 5 consecutive years, with -$248697.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Other Working Capital Changes rose 75.55% year-over-year to -$248697.0; the trailing twelve-month figure through Dec 2025 stood at $623705.0 (up 374.25% YoY), and the FY2025 full-year result was $623705.0, up 374.25% from the prior year.
- Other Working Capital Changes declined to -$248697.0 in Q4 2025 per CINGW's latest filing, from -$7341.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $1.7 million in Q3 2021 and bottomed at -$1.6 million in Q4 2021.
- Historically, Other Working Capital Changes has averaged $23417.0 across 5 years, with a median of $89976.5 in 2021.
- The sharpest annual moves came in 2022 and 2024: Other Working Capital Changes tumbled 308.88% in 2022, then soared 471.04% in 2024.
- Over 5 years, Other Working Capital Changes stood at -$1.6 million in 2021, then jumped by 118.13% to $287451.0 in 2022, then plunged by 238.71% to -$398730.0 in 2023, then plunged by 155.08% to -$1.0 million in 2024, then surged by 75.55% to -$248697.0 in 2025.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered -$248697.0, -$7341.0, and $358467.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.46 Bn | 623.70 Bn | 17.26 Bn |
| 2 | AbbVie | 440.11 Bn | 433.54 Bn | 12.70 Bn |
| 3 | Merck | 365.04 Bn | 357.90 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.82 Bn | 259.13 Bn | 11.24 Bn |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn |
| 6 | Sanofi | 52.47 Bn | 45.09 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.26 Bn | 44.26 Bn | - |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.46 Bn | 18.80 Bn | 683.80 Mn |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -248,697.00 |
| Dec 31, 2025 | -248,697.00 |
| Sep 30, 2025 | -7,341.00 |
| Sep 30, 2025 | -7,341.00 |
| Jun 30, 2025 | 358,467.00 |
| Jun 30, 2025 | 358,467.00 |
| Mar 31, 2025 | 521,276.00 |
| Mar 31, 2025 | 521,276.00 |
| Dec 31, 2024 | -1.02 Mn |
| Dec 31, 2024 | -1.02 Mn |
| Sep 30, 2024 | 830,401.00 |
| Sep 30, 2024 | 830,401.00 |
| Jun 30, 2024 | -1.14 Mn |
| Jun 30, 2024 | -1.14 Mn |
| Mar 31, 2024 | 1.10 Mn |
| Mar 31, 2024 | 1.10 Mn |
| Dec 31, 2023 | -398,730.00 |
| Dec 31, 2023 | -398,730.00 |
| Sep 30, 2023 | -742,270.00 |
| Sep 30, 2023 | -742,270.00 |